Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) to identify placebo-controlled or active-controlled RCTs using different GLP-1 RAs. We included eleven placebo-controlled or active-controlled phase-2 RCTs (involving a total of 936 middle-aged individuals) that used liraglutide (n = 6 RCTs), exenatide (n = 3 RCTs), dulaglutide (n = 1 RCT) or semaglutide (n = 1 RCT) to specifically treat NAFLD or NASH, detected by liver biopsy (n = 2 RCTs) or imaging techniques (n = 9 RCTs). Compared to placebo or reference therapy, treatment with GLP-1 RAs for a median of 26 weeks was associated with significant reductions in the absolute percentage of liver fat content on magnetic resonance-based techniques (pooled weighted mean difference: −3.92%, 95% confidence intervals (CI) −6.27% to −1.56%) and serum liver enzyme levels, as well as with greater histological resolution of NASH without worsening of liver fibrosis (pooled random-effects odds ratio 4.06, 95% CI 2.52–6.55; for liraglutide and semaglutide only). In conclusion, treatment with GLP-1 RAs (mostly liraglutide and semaglutide) is a promising treatment option for NAFLD or NASH that warrants further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent meta‐analysis consisting of 11 RCTs that investigated GLP‐1 agonists in NAFLD patients concluded that their overall clinical effect lies mainly in NASH resolution rather than fibrosis improvement [42].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The average HbA1c reduction with GLP-1RA in MASLD studies was estimated to be 0.5 % in individuals with and without type 2 diabetes [104] but may be substantially higher depending on the investigated compound and collective [105].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Specifically, the interpretation of the I 2 -statistics is as follows: I 2 -values of roughly 25% show low heterogeneity, I 2 -values of roughly 50% show medium heterogeneity, whereas I 2 -values of roughly 75% show high heterogeneity [65].”
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“We performed a systematic review and meta-analysis of RCTs in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (http://www.prisma-statement.org) [61].”
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 2×
“In addition, for continuous variables, if not available, SDs of the mean differences were estimated using the following formula: SD = [(SD pre-treatment) 2 + (SD post-treatment) 2 − (2R × SD pre-treatment × SD post-treatment)] 12 [64].”
InfluentialLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Wan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Cited by
Items 201–299 of 299
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
Baragetti, A. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.09 · Cited by 6
Koullias, E., Papavdi, M., Athanasopoulos, S., Mitrakou, A., Deutsch, M. J., Zoumpoulis, P. S., Manesis, E. K., Thanopoulou, A. C., & Koskinas, J. S. (2024) · Cureus · doi:10.7759/cureus.53813 · Cited by 4
“Relevant research regarding Dulaglutide, another member of the GLP1-ras family, is not as rich [7,8], with only one randomized controlled trial (RCT) studying its effect on liver fat content reduction.”
BackgroundHepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways
Yaribeygi, H., Kashian, K., Moghaddam, K. I., Karim, S. R., Bagheri, N., Karav, S., Jamialahmadi, T., Rizzo, M., & Sahebkar, A. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108928 · Cited by 4
Multi-Modality, Multi-Dimensional Characterization of Pediatric Non-Alcoholic Fatty Liver Disease
Jamshidi, N., Feizi, A., Sirlin, C. B., Lavine, J. E., & Kuo, M. (2023) · Metabolites · doi:10.3390/metabo13080929 · Cited by 5
“[36] recently evaluated the current state of randomized clinical trials for GLP-1 RA for the treatment of NAFLD/NASH, focusing on six placebo-controlled and five active-controlled studies.”
BackgroundResultInfluentialScheen, A. J. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2252333 · Cited by 6
“…with significant decreases in serum liver enzyme levels and absolute percentage of liver fat content assessed using magnetic resonance-based techniques, as well as with greater histological resolution of NASH without worsening liver fibrosis, when compared to placebo or reference therapies [67].”
Boutari, C., & Athyros, V. G. (2023) · Angiology · doi:10.1177/00033197231201706 · Cited by 3
The Evolving Role of GLP-1 Receptor Agonists in MASLD: Current Evidence and Future Directions
Zasadzińska, M., Borowski, G., Bakuła, P. R., & Jałocha, K. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_18_25 · Cited by 4
Overweight and obesity in metabolic syndrome
Nedogoda, S. V., & Васильевна, Ц. О. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6535 · Cited by 5
Alcohol-Associated Hepatitis: Translating Pathophysiology into Targeted Clinical Trials
Ma, J., Gao, H., Zeng, G., Huda, N., Jiang, Y., Thoudam, T., Yang, Z., & Liangpunsakul, S. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00703-9 · Cited by 4
Samuel, A. H., Kshatri, A. H. S., Babu, R. N., Patel, H. S., Viswanathan, S. H., Challa, M. S. R., & Swathi, N. L. (2026) · Annales d Endocrinologie · doi:10.1016/j.ando.2026.102494 · Cited by 4
Beyond medication: Unveiling the role of diet and lifestyle in fatty liver disease management
Ul‐Haq, I., Nadeem, M., Sharma, A., Mugabi, R., Waseem, M., & Nayik, G. A. (2025) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2025.200317 · Cited by 6
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 4
“However, no improvement in fibrosis stage without worsening MASH was observed, possibly due to short study durations and advanced baseline fibrosis [99].”
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
Mantovani, A. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.07.013 · Cited by 4
Self-citationTeufel, A., Geier, A., Sarrazin, C., Schattenberg, J. M., Kautz, A., Dorner, R., Kramer, J., Jerysiak, K., Baars, T., Hönscheid, B., et al. (2023) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1957-5671 · Cited by 6
Barazesh, M., Jalili, S., Akhzari, M., Faraji, F., & Khorramdin, E. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230417111247 · Cited by 3
Xie, S., Chen, D., Cai, Y., Xu, L., Liao, O., Jia, X., Ji, X., Chen, H., Mao, J., & Cai, J. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.022 · Cited by 3
Akhverdyan, N., Wieland, A. C., Sullivan, S. A., Lindsay, M., Swartwood, S., Arndt, G., Grau, L., & Jensen, T. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0115 · Cited by 5
Risk of cardio-nephro-metabolic disease from NAFLD to MAFLD: fact or fiction?
Hassouneh, R., Siddiqui, M. S., & Bhati, C. S. (2021) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2021.07 · Cited by 5
Vašura, A., Machytka, E., Urban, O., Macháčková, J., Pavliska, L., Berka, Z., Švagera, Z., & Bužga, M. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101765 · Cited by 2
Björnsdóttir, S., Ulfsdottir, H., Gudmundsson, E. F., Dobies, B., Sveinsdottir, K., Ísberg, A. P., Magnusdottir, G. E. A., Gunnarsdottir, T., Karlsdottir, T., Björnsdóttir, G., et al. (2025) · JMIR Cardio · doi:10.2196/72074 · Cited by 3
“They have been shown to improve glycemic control and reduce weight, insulin resistance, and liver fat content [38].”
Haff, M. G., Murabito, J. M., Vasan, R. S., Spartano, N. L., Liu, C., Zhang, X., Benjamin, E. J., Lewis, G. D., & Long, M. T. (2025) · Liver International · doi:10.1111/liv.70380 · Cited by 3
“Progression from simple steatosis to steatohepatitis, fibrosis and cirrhosis leads to an increasing risk of hepatic decompensation, morbidity and mortality [2–4].”
Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects
Piazzolla, V., Napolitano, A., & Mangia, A. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.152 · Cited by 2
Slaton, R. M., Iranikhah, M. G., & White, C. W. (2026) · JAPhA Pharmacotherapy · doi:10.1016/j.japhar.2026.100032 · Cited by 4
Aghemo, A., Armandi, A., Bugianesi, E., Cabibbo, G., Carbone, M., D’Ambrosio, R., Dalbeni, A., Cola, S. D., Gasbarrini, A., Germani, G., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.014 · Cited by 4
Alves, G. A. M., Teranishi, M., Majumdar, R., Khan, F., Dodeja, M., Ortega, A. C. T. D. C. G., Acerboni, M., Arachchige, A. S. P. M., & James, F. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70048 · Cited by 4
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Abdallfatah, A., Reyad, M., El‐Nemr, A. F., Maihoub, O., Elsekhary, A., Eladawi, S., Ayalew, B. D., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70222 · Cited by 4
Mahalingam, S., Kharbanda, K. K., Casey, C. A., & Rasineni, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1752204 · Cited by 3
“Furthermore, liraglutide and semaglutide have both demonstrated anti-fibrotic effects and their use in preclinical models prevents NASH-driven HCC progression (Sanyal et al., 2025; Mantovani et al., 2021).”
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 4
“Current human data most firmly support GLP-1–based ther - apy through reductions in liver fat content, improvement in liver enzyme profiles, increased likelihood of MASH reso - lution, and, in selected populations, histologic benefit with respect to fibrosis-related outcomes [ 50, 73, 161 ].”
Arab, J. P., Castro, L., GOMEZ, P. C., Vignolo, P., Arrese, M. A., Francisco Barrera, M., Castro, F., Díaz, L. A., Donoso, A., Elgueta, K., et al. (2021) · Revista médica de Chile · doi:10.4067/s0034-98872021000901360 · Cited by 8
Bentsa, T. М. (2023) · Modern Gastroenterology · doi:10.30978/mg-2023-6-59 · Cited by 4
NON-ALCOHOLIC FATTY LIVER DISEASE AND EXTRA-HEPATIC CANCER: A NARRATIVE REVIEW
de Rezende, A. Q. M., & Cazzo, E. (2024) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.24612023-027 · Cited by 3
Tapper, E. B., Ryan, T., Zeng, N., Carter, R., Winer-Jones, J. P., Bonafede, M., & Kim, Y. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0223 · Cited by 2
Lee, T., Wu, B.-J., Yu, C., & Wang, T.-J. (2021) · Taiwanese Journal of Psychiatry · doi:10.4103/tpsy.tpsy_38_21 · Cited by 3
Glucose-lowering agents and reduced risk of incident non-alcoholic fatty liver disease: new insights
Mantovani, A., Lombardi, R., & Dalbeni, A. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-2021-28 · Cited by 1
Self-citationComorbidity in adult psoriasis
Näslund‐Koch, C., Kaiser, H., & Skov, L. (2023) · doi:10.55788/723a4c4c · Cited by 1
Da NAFLD a MASLD: pillole per endocrinologi
Stasi, V. D., Maseroli, E., Pergola, G. D., & Vignozzi, L. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01564-6 · Cited by 1
“Dati meta-analitici evidenziano un effetto degli GLP1a sulla riduzione del contenuto di grasso intraepatico e sulla regressione dell’infiammazione all’esame istologico [28].”
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Year in Review: Selection of Best Papers in Gastroenterology and Hepatology 2024
Camilleri, M., & Dellon, E. S. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.06.001 · Cited by 1
Shi, J., Wu, X., Yu, J., & Zhou, Q. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1651357 · Cited by 2
Beyene, E., Chirumamilla, L. G., Bisrat, M., Bowen, A., Fetle, Y., Wilkerson, B., Wudeneh, A. T., Gillani, S. F., Larbi, D. A., & Michael, M. B. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102760 · Cited by 3
Current management of MASLD in type 2 diabetes
Fernández‐Garibay, V. M., Sarabia-Chao, V., & Chávez-Tapia, N. C. (2026) · HORMONES · doi:10.1007/s42000-026-00763-6 · Cited by 1
Berardicurti, A., D’Andrea, S., Cipollone, F., Berardicurti, O., Schiavone, C., & Boccatonda, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04384-0 · Cited by 1
Chianetta, R., Giannitrapani, L., Lipari, A. G., Brunone, A., Cannizzo, C., Citarrella, R., Soresi, M., Liguori, A., Panera, N., Morisco, F., et al. (2026) · Biomolecules · doi:10.3390/biom16060797 · Cited by 2
Incretin-based therapies: a new era in metabolic liver disease management
Elangovan, S., Cheah, C. C. M., & Goh, G. B. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.15 · Cited by 1
Peng, T., Lin, H., Tseng, T., Wu, T., & Chao, Y. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70629 · Cited by 2
“15,30 Unlike lifestyle-induced weight loss alone, semaglutide provides a consistent metabolic foundation that may stabilize disease activity even in patients who achieve more modest weight reduction.”
Guo, Y., Ma, Q., Guo, Z., Chu, J., Wu, N., & Yajuan, Q. I. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124534 · Cited by 4
Sümbül, H. E., Kırık, A., Yaylacı, S., Oral, A., Serın, S. O., Issever, K., Koca, N., Aydin, A., Demir, İ., Gözel, N., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11139-8 · Cited by 1
Ye, J., Qi, Y., Chen, J., Zhang, S., Liu, B., Zhao, Y., Yuan, X., Cheng, Q., Yang, Y., Zhang, F., et al. (2023) · Advanced Biology · doi:10.1002/adbi.202200150 · Cited by 1
Novel Therapeutics in Nonalcoholic Fatty Liver Disease: A Focus on Adult Stem Cells
Nandula, S. R., Nylén, E., & Sen, S. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0069 · Cited by 3
From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis
Aggarwal, M., & Lindenmeyer, C. C. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000005 · Cited by 1
“Glucagon-like peptide 1 agonists and sodium glucose cotransporter 2 inhibitors, which have become front line therapy for DM, have shown benefit in NASH resolution, hepatocellular lipid content and liver biochemical test improvement.[19,20] Peroxisome proliferator-activated receptor agonist, another class of DM agents,…”
BackgroundWhich patient should have preference for liver transplantation: ALD?
Mazhar, A., Alnimer, L., & Piper, M. S. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000009 · Cited by 1
“[30] In another study, bariatric surgery resulted in biopsy confirmed resolution of steatosis in 66% of patients, fibrosis in 40%, and a significant reduction in mean NAFLD activity score (NAS) (mean difference, 2.39; 95% CI, 1.58 – 3.20).”
BackgroundInfluentialStationäre Patienten mit der Nebendiagnose Diabetes mellitus: klinische Relevanz
Jenssen, C., & Pietsch, C. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00897-2 · Cited by 2
Okamoto, A., Yokokawa, H., Nagamine, T., Fukuda, H., Hisaoka, T., & Naito, T. (2021) · Research Square · doi:10.21203/rs.3.rs-586388/v1 · Cited by 1
Liu, B., Peng, G., Yin, Y., Shen, C., Yin, X., Cai, Z., & Zhang, B. (2024) · Gut · doi:10.1136/gutjnl-2024-332254 · Cited by 2
Ruolo dei farmaci antidiabete nel trattamento della NAFLD
Mantovani, A. (2021) · il Diabete · doi:10.30682/ildia2102b
Self-citationKhalifa, O., Al-Akl, N. S., Errafii, K., & Arredouani, A. (2021) · Research Square · doi:10.21203/rs.3.rs-898584/v1
Obesity - Recent Insights and Therapeutic Options
McFarlane, S. I. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104318
Суплотова, Л. А., Fedorova, A. I., Kulmametova, D. S., Сергеевна, Д. Т., & Makarova, O. B. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-23-148-155
Mucinski, J. M. (2022) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/93980
Novel Anti-Obesity Pharmacotherapies
Ghomraoui, F., & Srivastava, G. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110685
Teplyuk, D. A., Kaisina, A. A., Ibragimova, S. I., Bestavashvili, A., Тинькова, И. О., Pashkova, E. Y., Kaibullayeva, J. A., Nersesov, A., & Pavlov, C. S. (2023) · Consilium Medicum · doi:10.26442/20751753.2023.5.202272 · Cited by 2
Al‐Sabah, S., Jamal, M. H., Al‐Khaledi, G., Dsouza, C. L., AlOtaibi, F., Al-Ali, W., Cherian, P., Al‐Khairi, I., Ali, H., Abu‐Farha, M., et al. (2023) · Medical Principles and Practice · doi:10.1159/000533746 · Cited by 1
“Both bariatric surgery and GLP-1 receptor agonists have been shown to ameliorate NAFLD [28, 29].”
BackgroundTkach, S. M. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-3-62 · Cited by 1
(2023) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2149-7976
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
As, A., & Туркина, С. В. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-4-87-98
Chen, J., & Wu, H. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.123002
Park, S. J., Ha, Y., Lee, J. H., Lee, K., & Chon, Y. E. (2024) · Research Square · doi:10.21203/rs.3.rs-4183955/v1
Future directions for fatty liver disease
Bartolomeo, A. D., & George, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00016-9
Doença Hepática Esteatótica associada à disfunção metabólica
Gusmao, L. V., Ramos, A. C. R., Remigio, G. C. B., Baiardi, V. C. S., & Gonçalves, B. P. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n4-173
Şimşek, C., & Thompson, C. C. (2024) · Springer eBooks · doi:10.1007/978-3-031-70004-0_3
Zhao, Y., Bi, Y., Zhang, W., Li, K., Lin, G., Lin, X., Chen, Y., Jiang, X., Zhao, X., & Fan, H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5163154
Non-alcoholic fatty liver disease and chronic kidney disease
Туркина, С. В., Андреевна, Т. И., & Титаренко, М. Н. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-49-61 · Cited by 1
Bzoma, M., Bochenek, H., Kamiński, P., Czerepak, I., Gugulska, J., Bielicka, A., Szwarc, T., Kałwik, M., Niewczas, K., & Brzozowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3493
Targeting autophagy in metabolic diseases
Heidari, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00017-2
Metabolic dysfunction-associated steatotic liver disease in metabolic syndrome
Drapkina, O. M., & Nedogoda, S. V. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6541 · Cited by 4
Seramur, M. E., SINK, S. T., Reeves, T. E., Woods, L. C. S., & Chuang, C. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153078
Pharmacogenetic Insights into Glucagon-Like Peptide-1 Receptor and Its Role in Diabetes Therapy
Davis, C., Taylor, L., & Moore, I. (2023) · Annals of Pharmacy Practice and Pharmacotherapy · doi:10.51847/qbaabzn70k
Giannitrapani, L., Ferraro, M., Seidita, A., Licata, A., & Soresi, M. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i12.110076
Duodenal mucosal intervention in the management of MASLD and type 2 diabetes
Saeed, Z., Liu, B., Yousaf, M., & Liu, W. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02023-w · Cited by 1
Lee, J. Y.-C., Nguyen, H., & Nguyen, T. (2026) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1596_25
Zurakowski, G., Wiela−Hojeńska, A., & Petryszyn, P. W. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072621 · Cited by 1
Patil, N. Y., Mare, R., Rus, I., Scionti, F., Powell, J., Eeda, V., Joshi, A., & Awasthi, V. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119544
Ikonomidis, I., Michalopoulou, E., Pavlidis, G., Nikolaou, P., Katogiannis, K., Prentza, V., Thymis, J., Vlachomitros, D., Katsanaki, E., Kostelli, G., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004311
Wu, H., Zhang, Z., Ye, T., Chen, J.-N., Tung, T., & Zhu, J. F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1783429
Hepatic steatosis: A pandemic disease causing serious secondary diseases
Canbay, A., Figge, A., Patsalis, P., Baars, T., Özcürümez, M. K., & Götze, O. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2026.0074
Hu, J.-H., Chang, M., Huang, T., Liu, N., & Hsieh, Y.-Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1874720
“Several prior syntheses have examined GLP-1RAs, SGLT2 inhibitors, and liver-related endpoints, including recent network meta-analytic work that ranked drug classes across heterogeneous liver-related outcomes (8 – 10).”
Post-transplant MASLD: a risk-stratified approach to assessment and personalized management
Huang, H.-Y., Fan, Z., & Lv, G.-Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1878245 · Cited by 1
Wang, X., Su, G., Ge, F., Miao, W., Li, L., Li, Z., Yu, J. H., Jiang, H., Ma, Y., Yu, Z., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158432
Solís, R. S., Baeza-Zapata, A., & Negrete‐Najar, J. P. (2026) · Cureus · doi:10.7759/cureus.111728
Prabhu, S., Suresh, M., & Stalin, A. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147085
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
Primary Care Approaches to MASLD in Type 2 Diabetes
Lam, E., & Shubrook, J. H. (2026) · Journal of the Osteopathic Family Physicians of California · doi:10.58858/050301
Koutouratsas, T., Kalligeros, M., Michael, M., Das, S., Mylonakis, S. C., & Mylonakis, E. E. (2026) · Age and Ageing · doi:10.1093/ageing/afag281 · Cited by 1
Boutari, C., Charalampidis, K., Sideras, L., Sinakos, E., & Goulis, I. (2026) · Life · doi:10.3390/life16101656
Araujo, M. E. F. S., da Silva, E. P. V., Baccin, E. A., Faria, J. D. O., Schnorrenberger, K., & Wolniewicz, L. B. (2026) · Arquivos Catarinenses de Medicina · doi:10.63845/6qvyhk61
Alfawaz, M. A., Bajamaan, D., Alghamdi, L. S., Alorfi, Y. A., Khared, S., Ameen, N., Alamri, R., Abuladel, M., Alshehri, R., & Altowairqi, S. (2026) · Medicine · doi:10.1097/md.0000000000051306
“This finding aligns closely with the direction and magnitude reported in an updated meta-analysis of phase 2 RCTs by Mantovani and colleagues, [20] which found a significant reduction in MRI-assessed absolute liver fat percentage (WMD= −3.9) over a median treatment duration of 26 weeks.”
Influential
Metadata
- Authors
- Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G.
- Affiliations
- University of Verona (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Corresponding author
- Targher, Giovanni
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2021-01-27
- Volume
- 11
- Issue
- 2
- Pages
- 73
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC7911747
- OpenAlex
- W3126030429
- Cited by
- 299
- References
- 68
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 54 · 2023: 61 · 2022: 61 · 2021: 35
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- GLP-1 receptor agonists, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liraglutide, semaglutide, exenatide, dulaglutide, liver fat, liver enzymes, liver fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.